Leap Therapeutics Inc. (LPTX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Leap Therapeutics Statistics
Share Statistics
Leap Therapeutics has 38.32M shares outstanding. The number of shares has increased by 49.68% in one year.
Shares Outstanding | 38.32M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.14% |
Owned by Institutions (%) | n/a |
Shares Floating | 28.57M |
Failed to Deliver (FTD) Shares | 4.76K |
FTD / Avg. Volume | 1.12% |
Short Selling Information
The latest short interest is 1.01M, so 2.63% of the outstanding shares have been sold short.
Short Interest | 1.01M |
Short % of Shares Out | 2.63% |
Short % of Float | 3.53% |
Short Ratio (days to cover) | 2.68 |
Valuation Ratios
The PE ratio is -1.04 and the forward PE ratio is -2.6.
PE Ratio | -1.04 |
Forward PE | -2.6 |
PS Ratio | 0 |
Forward PS | 16.3 |
PB Ratio | 1.41 |
P/FCF Ratio | -1.93 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Leap Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.64, with a Debt / Equity ratio of 0.
Current Ratio | 5.64 |
Quick Ratio | 5.64 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0.43 |
Cash Flow / Debt | -167 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.35% and return on capital (ROIC) is -144.1%.
Return on Equity (ROE) | -1.35% |
Return on Assets (ROA) | -1.12% |
Return on Capital (ROIC) | -144.1% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.51M |
Employee Count | 54 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -20.06% in the last 52 weeks. The beta is 0.22, so Leap Therapeutics 's price volatility has been higher than the market average.
Beta | 0.22 |
52-Week Price Change | -20.06% |
50-Day Moving Average | 3.02 |
200-Day Moving Average | 2.71 |
Relative Strength Index (RSI) | 37.31 |
Average Volume (20 Days) | 423.72K |
Income Statement
Revenue | n/a |
Gross Profit | -427.00K |
Operating Income | -87.04M |
Net Income | -81.41M |
EBITDA | -80.99M |
EBIT | n/a |
Earnings Per Share (EPS) | -3.98 |
Balance Sheet
The company has 70.64M in cash and 262.00K in debt, giving a net cash position of 70.38M.
Cash & Cash Equivalents | 70.64M |
Total Debt | 262.00K |
Net Cash | 70.38M |
Retained Earnings | -399.58M |
Total Assets | 65.05M |
Working Capital | 47.72M |
Cash Flow
In the last 12 months, operating cash flow was -43.75M and capital expenditures 0, giving a free cash flow of -43.75M.
Operating Cash Flow | -43.75M |
Capital Expenditures | 0 |
Free Cash Flow | -43.75M |
FCF Per Share | -2.14 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
LPTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -156.08% |
FCF Yield | -44.78% |
Analyst Forecast
The average price target for LPTX is $8, which is 213.7% higher than the current price. The consensus rating is "Buy".
Price Target | $8 |
Price Target Difference | 213.7% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Stock Splits
The last stock split was on Jun 21, 2023. It was a backward split with a ratio of 1:10.
Last Split Date | Jun 21, 2023 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -7.82 |
Piotroski F-Score | 2 |